A report by the UK Bio Industry Association (BIA) and Informa Pharmaceutical Intelligence recorded that the UK biotech sector raised £2.2bn from investors in 2018, an 85 percent increase compared to the 2017 figure of £1.2bn and the highest since the BIA’s first report in 2013. The report also highlighted the innovative nature of the biotech start-up sector in the UK and its ability to make use of new technology. The emergence of new business models in areas such as artificial intelligence (AI) has proved to be a boon for drug discovery, development, and various other purposes.
The innovation efforts of a number of biotech start-ups across the UK are directly benefitting from the increased investments, resulting in faster and more effective translation of research results into practical applications. These start-ups are developing a wide range of advanced solutions including gene therapies for inherited conditions that affect the immune system, an antiviral drug against the respiratory syncytial virus (RSV), treatments for disorders of the nervous system, and more. Spin-offs of major universities in the UK are also contributing significantly to the advancement of the biotechnology industry. One such start-up focuses on the development of next-generation CAR-T therapy, aiming to reduce the life-threatening side effects of this kind of treatment by killing cancer cells without affecting the healthy T cells.
As investments in the biotech start-up sector soar, along with various emerging technologies, organizations must focus on selecting the biotech offering that best addresses their business requirements. In this regard, our distinguished panel comprising key decision makers and experts along with StartupCity’s editorial board has shortlisted some of the most promising biotech start-ups in the UK.
We present to you StartupCity’s “15 Most Promising BioTech Startups in UK - 2019.”
